Why Goldman Sachs sees 13% upside for the ResMed share price

Here’s why ResMed shares could be in the buy zone…

| More on:
An ASX shares broker analysing a chart tracking the A2 Milk share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price was on form on Friday.

The sleep treatment focused medical device company’s shares rose almost 3% to $30.45.

Can the ResMed share price keep rising?

The good news for investors is that one leading broker still sees plenty of room for the ResMed share price to keep rising.

According to a recent note out of Goldman Sachs, its analysts have a buy rating and $34.40 price target on its shares.

This implies potential upside of 13% for investors over the next 12 months.

What did the broker say?

Goldman notes that ResMed has announced plans to acquire Medifox Dan for US$1 billion.

It is an out-of-hospital software provider based in Germany which generated revenue of US$83 million and EBITDA of US$35 million in calendar year 2021.

Goldman appeared pleased with the deal. It commented:

The acquisition goes some way to answering a long-held question the market has had around when/how the company would attempt to replicate its SaaS strategy outside of the US market.

What else is the broker saying?

Its analysts also highlight that the ResMed share price has been underperforming in FY 2022 due to concerns over supply chain headwinds. This has stopped the company from taking full advantage of a major product recall from rival Philips.

However, Goldman feels the market is overreacting and expects elevated demand to stick around long enough for ResMed to benefit. It also sees a backlog of patients waiting to be diagnosed as a potential upside risk to estimates.

Its analysts explained:

We believe the elevation in demand could persist beyond the time it takes for component shortages to improve (via both external and internal factors) and, as such, the YTD underperformance of the shares may be over-capitalising relatively short-term headwinds.

We believe the backlog of new patients may add upside to our estimates if there is a material realisation of incremental devices/masks sales to new patients in FY23/24 (supply chain pressures permitting). The return of PHIA to the market may actually help in this regard, as the company supplies critical diagnosis equipment.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Why this broker sees plenty of upside for the ResMed share price

ResMed shares could be in the buy zone...

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Looking to buy CSL shares? Here’s what to watch when the biotech company reports this week

Here’s what might be around the corner for CSL this earnings season.

Read more »

A scientist examining test results.
Healthcare Shares

Why did the Opthea share price dive 9% on Monday?

The biopharmaceutical company has announced new share issue arrangements.

Read more »

A disappointed female investor sits in front of her laptop and puts her hand to her forehead and closes her eyes in disappointment over share price falls
Capital Raising

Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise

Paradigm shares have erased all of last week's gains...

Read more »

A woman stands facing a set of shelves that is completely empty.
Healthcare Shares

The ASX 200 company selling everything it makes due to its major competitor being out of the market: fundie

ResMed is performing strongly right now.

Read more »

a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.
Healthcare Shares

Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »